WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

  • 4.25.2017

Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced that two additional pharmaceutical companies, Pfizer Inc. and AbbVie Inc., have invested in their work to treat Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment, that WilmerHale also handled, made by Takeda Pharmaceuticals in December 2015.

The WilmerHale team counseling Aquinnah Pharmaceuticals included Joshua Fox and Stephanie Singer.

Read Aquinnah Pharmaceuticals' press release for more information.

Not sure where to start?

Let our Knowledge Navigator direct you to content specific to where you are on your journey.

Get Started!
Featured
blog-launch-550x370

This blog post explores certain specific terms in term sheets that will create legally binding obligations.

Schall launch feature

Partner Gary Schall shares some practical advice about term sheets: Don’t attempt any transaction without one.

Rss Feed
2.22.2025
We need to talk about the F word (‘friction’ in enterprise, that is) 
2.22.2025
The rise of browser-use agents: Why Convergence’s Proxy is beating OpenAI’s Operator 
2.22.2025
Meta launches $50M Meta Horizon Creator Fund 
Build
Document Generator  
Startup Dictionary  
2.20.2025
Corporate Transparency Act: Judge Clears Way for CTA; Reporting Requirements Back in Effect
2.12.2025
Corporate Transparency Act: It’s Still Paused (For Now)
12.27.2024
Corporate Transparency Act: Preliminary Injunctive Relief Reinstated by Fifth Circuit (For Now)